



HAL
open science

Control of dengue virus in the midgut of *Aedes aegypti* by ectopic expression of the dsRNA-binding protein **Loqs2**

Roenick Proveti Olmo, Alvaro G. A. Ferreira, Tatiane C. Izidoro-Toledo, Eric R. G. R. Aguiar, Isaque Joao da Silva de Faria, Kátia P. R. de Souza, Kátia P. Osório, Lauriane Kuhn, Philippe Hammann, Elisa Goncalves de Andrade,
et al.

► To cite this version:

Roenick Proveti Olmo, Alvaro G. A. Ferreira, Tatiane C. Izidoro-Toledo, Eric R. G. R. Aguiar, Isaque Joao da Silva de Faria, et al.. Control of dengue virus in the midgut of *Aedes aegypti* by ectopic expression of the dsRNA-binding protein Loqs2. *Nature Microbiology*, 2018, 3 (12), pp.1385-1393. 10.1038/s41564-018-0268-6 . hal-03596805

HAL Id: hal-03596805

<https://hal.science/hal-03596805>

Submitted on 3 Mar 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Control of Dengue virus in the midgut of *Aedes aegypti* by ectopic expression of the**
2 **dsRNA binding protein Loqs2**

3

4 Roenick P. Olmo^{1,2}, Alvaro G. A. Ferreira¹, Tatiane C. Izidoro-Toledo¹, Eric R. G. R. Aguiar^{1,2},
5 Isaque J. S. de Faria^{1,2}, Kátia P. R. de Souza¹, Kátia P. Osório¹, Lauriane Kuhn³, Philippe
6 Hammann³, Elisa G. de Andrade¹, Yaovi Mathias Todjro¹, Marcelle N. Rocha⁴, Thiago H. J. F.
7 Leite¹, Siad C. G. Amadou¹, Juliana N. Armache¹, Simona Paro², Caroline D. de Oliveira⁴, Fabiano
8 D. Carvalho⁴, Luciano A. Moreira⁴, Eric Marois², Jean-Luc Imler², João T. Marques^{1,2*}

9

10 ¹Department of Biochemistry and Immunology, Instituto de Ciências Biológicas, Universidade
11 Federal de Minas Gerais, Belo Horizonte/MG, 31270-901, Brazil.

12 ²Université de Strasbourg, CNRS UPR9022, Inserm U1257, 67084 Strasbourg, France.

13 ³Plateforme Protéomique Strasbourg-Esplanade FRC 1589, Institut de Biologie Moléculaire et
14 Cellulaire, 67084 Strasbourg, France.

15 ⁴Mosquitos Vetores: Endossimbiontes e Interação Patógeno-Vetor, Instituto de Pesquisas René
16 Rachou - Fiocruz, Belo Horizonte/MG, 30190-002, Brazil.

17

18 *e-mail: jtm@ufmg.br

19

20 Dengue virus (DENV) is an arbovirus transmitted to humans by *Aedes* mosquitoes¹. In the
21 insect vector, the small interfering RNA (siRNA) pathway is an important antiviral
22 mechanism against DENV²⁻⁵. However, it remains unclear when and where the siRNA
23 pathway acts during the virus cycle. Here, we show that the siRNA pathway fails to
24 efficiently silence DENV in the midgut of *Aedes aegypti* although it is essential to restrict
25 systemic replication. Accumulation of DENV-derived siRNAs in the midgut reveals that
26 impaired silencing results from a defect downstream of small RNA biogenesis. Notably,
27 silencing triggered by endogenous and exogenous dsRNAs remained effective in the
28 midgut where known components of the siRNA pathway, including the dsRNA binding
29 proteins Loquacious and r2d2, had normal expression levels. We identified an *Aedes*
30 specific paralog of *loquacious* and *r2d2*, hereafter named *loqs2*, which is not expressed in
31 the midgut. Loqs2 interacts with Loquacious and r2d2 and is required to control systemic
32 replication of DENV and also Zika virus (ZIKV). Furthermore, ectopic expression of Loqs2
33 in the midgut of transgenic mosquitoes is sufficient to restrict DENV replication and
34 dissemination. Together our data reveal a mechanism of tissue specific regulation of the
35 mosquito siRNA pathway controlled by Loqs2.

36
37 Previous studies observed production of DENV-derived siRNAs and piwi-interacting RNAs
38 (piRNAs) in infected mosquitoes and suggested that different RNA interference (RNAi)
39 mechanisms were important to control virus replication^{2,3,6,7}. In order to investigate the activation
40 of RNAi by DENV infection in mosquitoes, we first analyzed different concentrations of the virus
41 in the blood meal (Supplementary Fig. 1a,b). Using 10⁷ PFU/mL of virus, we observed that 100%
42 of individual mosquitoes had detectable virus at 1 and 2 days post feeding (dpf) (Fig. 1a). This
43 likely corresponds to the virus inoculum in the blood meal since the amount of viral RNA
44 decreased until 4 dpf when mosquitoes have completed blood digestion⁸. At this point, viral RNA
45 could not be detected in some mosquitoes, suggesting that they had cleared the virus (defined

46 as undetectable group). Other individuals had detectable levels of viral RNA but below the lowest
47 signal detected at 2 dpf (low viral load group). The third group of mosquitoes had viral RNA levels
48 similar or higher than the inoculum detected at 2 dpf (high viral load group). At 8 and 14 dpf, we
49 noted a decrease in mosquitoes in the low viral load group and a concomitant increase in
50 mosquitoes with no detectable viral RNA (Fig. 1a). The antigenome of DENV could not be
51 amplified by strand-specific RT-PCR in the “undetectable” group, and only trace amounts were
52 observed at the latest time points in the “low” group (Fig. 1b). By contrast, the DENV antigenome
53 was readily detectable as early as 4 dpf in the “high” group, indicating that the virus was actively
54 replicating in these individuals. We interpret that these different groups of mosquitoes represent
55 individuals that eliminated the virus (“undetected”), are in the process of eliminating/controlling
56 the virus (“low viral load”) or were productively infected (“high viral load”).

57
58 To determine if RNAi contributes to clearance/control of the virus, we deep-sequenced small
59 RNAs from the 3 groups of mosquitoes at different time points (Fig. 1c-e). Mosquitoes given a
60 non-infectious blood meal were used as controls (Fig. 1f). Production of DENV-derived siRNA (21
61 nt accumulation with symmetrical distribution between sense and antisense strands) was only
62 observed in individuals with high viral load (Fig. 1c). Production of virus-derived siRNAs in these
63 mosquitoes increased with time and correlated with viral load ($r=0.92$, $p=0.0079$). A few dozen
64 reads per million (RPM) of virus-derived small RNAs were detected throughout the kinetics of
65 infection in individuals with low viral load, but these had a broad size profile suggestive of random
66 degradation products⁹ (Fig. 1d). Mosquitoes from the undetectable group had background
67 amounts of virus-derived small RNAs similar to the uninfected control group in the order of less
68 than 10 RPM (Fig. 1e,f). We conclude that the siRNA pathway was likely not responsible for
69 elimination or control of DENV in these mosquitoes where the infection was presumably restricted
70 to the midgut^{10,11}. Of note, the few observed DENV-derived small RNAs with sizes matching that
71 of piRNAs (24-29 nt) lacked canonical characteristics of the piRNA pathway such as a 5' U

72 enrichment and 10-nt overlap between strands as a result of the ping-pong mechanism⁹. We next
73 injected the virus into the hemocoel of mosquitoes to monitor the response to direct systemic
74 infection. In this case, all mosquitoes became infected and the viral load increased similarly over
75 time even at the lowest dose (Supplementary Fig. 1c). Mosquitoes injected with 160 PFU, where
76 viral replication was kinetically similar to individuals fed with 10⁷ PFU/mL (Compare Fig. 1a and
77 Fig. 1g), showed production of DENV-derived siRNAs as early as 1 day post injection (dpi) (Fig.
78 1h). This response increased proportionally to viral RNA levels ($r=0.99$, $p=0.0052$) (Fig. 1h). The
79 similarity in the small RNA profiles observed between the high viral load group after a blood meal
80 and the injection group suggests that the siRNA pathway is strongly activated once the virus
81 disseminates systemically. Here again, we did not observe production of virus-derived piRNAs
82 (Fig 1h).

83
84 We next assessed the impact of mosquito RNAi on different outputs of DENV infection (Fig. 2a)
85 by silencing AGO2, the core component of the siRNA induced silencing complex¹². Injection of
86 dsRNA complementary to AGO2 (dsAGO2) led to 85.7% silencing of this gene in the midgut
87 compared to a control targeting the firefly *Luciferase* gene (dsFLUC) (Supplementary Fig. 2a).
88 Despite efficient silencing, dsAGO2 treated mosquitoes did not show an increase in viral load nor
89 prevalence of infection in the midgut at 3 and 4 dpf (Fig. 2b,c). To directly monitor viral replication
90 in the midgut, we used immunofluorescence microscopy with antibodies recognizing the viral
91 envelope (E) protein (Supplementary Fig. 2b). Quantification of imaging results showed that
92 numbers of DENV infection foci per midgut did not increase in dsAGO2 treated mosquitoes
93 compared to controls and was even slightly decreased (Fig. 2d). Furthermore, there was no
94 difference in the size of the infection foci between dsAGO2 and control mosquitoes (Fig. 2e).
95 These results confirm that the siRNA pathway has limited impact, if any, on the control of early
96 DENV infection or replication in the mosquito midgut.

97

98 We next analyzed the carcasses of the same mosquitoes that were infected by an infectious blood
99 meal. At 3 and 4 dpf, there was no significant difference between viral load in the carcass of
100 control and dsAGO2 treated mosquitoes (Fig. 2f). Control and dsAGO2 treated mosquitoes also
101 showed little systemic dissemination of DENV as indicated by the low prevalence of infection in
102 the carcass (Fig. 2g). In contrast, dsAGO2 treated mosquitoes had significantly higher prevalence
103 of disseminated infection at 8 dpf, even though viral RNA levels were not significantly increased
104 at this time point (Fig. 2f,g). These results suggest that AGO2 controls viral replication upon
105 systemic dissemination. Indeed, upon DENV injection into the hemocoel of mosquitoes, which
106 results in direct systemic infection, viral load was significantly increased in dsAGO2 treated
107 individuals (Fig. 2h). Altogether, our findings reveal that the siRNA pathway controls systemic
108 infection by DENV but fails to efficiently restrict the virus in the midgut.

109
110 Curiously however, the siRNA pathway appears to be functional in the midgut since *AGO2*
111 expression is efficiently silenced by injected long exogenous dsRNA (Supplementary Fig. 2a).
112 Accordingly, core components of the pathway (*Dcr-2*, *r2d2*, *AGO2*, *Hen1* and *loqs-RA*) are
113 expressed in the midgut at similar or higher levels than in whole mosquitoes (Fig. 3a).
114 Furthermore, transposable elements (TEs), which are controlled by the endogenous siRNA
115 pathway in somatic tissues of insects¹³, were significantly upregulated in the midgut of dsAGO2
116 treated mosquitoes compared to controls (Fig. 3b). These results suggest that the siRNA pathway
117 is fully functional in the midgut when activated by endogenous and exogenous sources of dsRNA.

118
119 To test whether DENV is resistant to AGO2 mediated gene silencing in the midgut, we engaged
120 the exo-siRNA pathway by injecting mosquitoes with dsRNA targeting the NS3 region of DENV
121 (dsDENV) before infection by feeding. This resulted in abundant production of DENV-derived
122 siRNAs and efficient control of viral replication in the midgut (Fig. 3c-e). Overall, our data indicate
123 that silencing triggered DENV infection is mechanistically different from endogenous and

124 exogenous sources of dsRNA. We observed production of DENV-derived siRNAs in the midgut
125 even before they were detected in the carcass of orally infected mosquitoes indicating that any
126 defect in antiviral RNAi is downstream of small RNA biogenesis (Fig. 3f).

127

128 Our results suggest that siRNAs directly produced from a viral substrate are not functional
129 silencing in the midgut, in contrast to exo- and endo-siRNAs. These results imply that the
130 mosquito siRNA pathway discriminates dsRNAs from viral origin as observed in *Drosophila*¹⁴ and
131 *Caenorhabditis elegans*¹⁵. Small dsRBPs often regulate different steps of RNA silencing^{17,19-21}
132 and allow functional specialization without requiring significant changes in core components of
133 the siRNA pathway¹⁴. In *Drosophila*, two dsRNA binding proteins (dsRBPs), Loquacious and r2d2,
134 regulate biogenesis and loading of siRNAs^{14,16,17}. Loqs-PD is encoded by an isoform of the
135 *loquacious* gene and is required for silencing of endogenous and exogenous sources of dsRNA
136 but not viruses. The Loqs-PD isoform appeared recently in the *Drosophila* lineage¹⁸. In *A. aegypti*,
137 Loqs-PA encoded by a different isoform of *loquacious* is required for the biogenesis of siRNAs
138 but it does not discriminate viral and endogenous sources of dsRNA¹⁸. We analyzed the genome
139 of *A. aegypti* to find genes encoding other dsRBPs and identified an uncharacterized gene,
140 *AAEL013721*. Phylogenetic analysis and domain organization indicated that this putative dsRBP
141 is a paralog of both *r2d2* and *loquacious*, more closely related to the latter (Fig. 4a). Hereafter we
142 refer to *AAEL013721* as *loqs2*. The *loqs2* gene is found in the genomes of *A. aegypti* and *A.*
143 *albopictus* but not in other mosquitoes such as *Culex* and *Anopheles* (Fig. 4a). The *loqs2* gene is
144 widely expressed in most organs from *A. aegypti* but not in the midgut (Fig. 3a). In order to
145 address the contribution of *loqs2* to antiviral defense during systemic infection, we silenced its
146 expression before direct systemic injection of DENV. Mosquitoes treated with dsRNA targeting
147 *loqs2* (dsLoqs2) showed significantly increased levels of DENV RNA (Fig. 4b). These results
148 show that Loqs2 is required to control systemic viral infection. Because *loqs2* is not expressed in
149 the midgut, we hypothesized that it is the missing cofactor for antiviral RNAi in this tissue. We

150 next generated transgenic mosquitoes expressing *loqs2* under the control of the
151 *carboxypeptidase (CP)* gene that directs midgut expression in response to blood feeding²² (Fig.
152 4c-e). The transgene was inherited at normal Mendelian ratios and mosquitoes showed no visible
153 abnormalities. When exposed to an infectious blood meal, transgenic mosquitoes showed
154 significantly reduced DENV load in the midgut at 4 and 8 dpf (Fig. 4f,g). This likely resulted in
155 lower virus dissemination since the prevalence of infection was significantly reduced in the
156 carcass of transgenic mosquitoes (Fig. 4h,i). To identify potential protein partners, we
157 immunoprecipitated Loqs2 from Aag2 cells and performed mass spectrometry analysis (Fig. 4j).
158 A total of 79 proteins were significantly enriched in the Loqs2 immunoprecipitation compared to
159 the control (Supplementary Table 1). Loqs and r2d2, the two dsRBPs involved in siRNA
160 biogenesis and loading, were among the 4 most significant hits (Fig. 4j). These results suggest
161 that Loqs2 works together with Loqs and r2d2 to allow the siRNA pathway to control viral infection.
162 In order to evaluate whether Loqs2 was broadly required for the control of arboviruses, we
163 analyzed ZIKV infection in mosquitoes. The prevalence of disseminated ZIKV infection in the
164 carcass after an infectious blood meal was low at 4 dpf and increased by 8 dpf (Supplementary
165 Fig. 3a,b). In contrast, mosquitoes treated with dsRNA to silence *loqs2* (dsLoqs2) had significantly
166 increased ZIKV replication and dissemination to the carcass at 4 dpf compared to control
167 mosquitoes (Supplementary Fig. 3c,d). These data suggest that Loqs2 is also important to control
168 ZIKV dissemination.

169
170 In summary, our results reveal that the siRNA pathway controls DENV and ZIKV infection during
171 systemic dissemination but not in the midgut. Interestingly, control of O'nyong-nyong virus in the
172 midgut of *Anopheles* mosquitoes also seems to be independent on the siRNA pathway²³. This
173 tissue-specific defect suggests the existence of specialization in the mosquito siRNA pathway
174 since silencing triggered by exogenous and endogenous dsRNAs appears fully operational in the
175 midgut. Functional specialization of the siRNA pathway in response to viruses has been reported

176 in different organisms and might be required for optimizing the antiviral defense^{14,24-26}. We
177 identified an *Aedes* specific dsRBP, Loqs2, that is required for systemic control of DENV likely by
178 regulating the antiviral arm of the siRNA pathway. Further studies are necessary to determine
179 how Loqs2 would specifically affect antiviral silencing but not the siRNA pathway triggered by
180 endogenous and exogenous sources of dsRNA. It is also unclear why *loqs2* is not expressed in
181 the midgut, unlike other components of the siRNA pathway. The Loqs-PD isoform in *Drosophila*
182 and *loqs2* in *Aedes* mosquitoes evolved independently, suggesting there is selective pressure to
183 separate the antiviral arm of the siRNA pathway. Finally, it is interesting to speculate whether the
184 specialization of the siRNA pathway we described in *Aedes* mosquitoes is connected to their
185 exquisite vector competence for viruses.

186

187 **Methods**

188

189 **Ethics statement.** All procedures involving vertebrate animals were approved by the ethical
190 review committee of the Universidade Federal de Minas Gerais (CEUA 337/2016 to J.T.M.). Blood
191 for membrane feeding was obtained from a blood bank in Belo Horizonte (Brazil) accordingly to
192 protocol approved by the Committee for Ethics in Research (CEP)/FIOCRUZ (License CEP
193 732.621 to L.A.M.).

194 **Virus propagation.** Viral isolates of DENV4 (H241 strain), DENV1²⁷ and ZIKV (PE243/2015)²⁸
195 were propagated in C6/36 *A. albopictus* cells maintained on L15 medium supplemented with 5%
196 FBS (fetal bovine serum), penicillin, streptomycin and gentamycin as described²⁹. Briefly, cells
197 were seeded to 70% confluency and infected at a multiplicity of infection (MOI) of 0.01. Culture
198 was maintained for 9 days at 28°C and supernatant was collected apart from cells, that were lysed
199 by repeated freezing and thawing for releasing virus particles and mixed to supernatant. After
200 clarifying the supernatant by centrifugation, virus stocks were kept at -80°C prior to use. Mock-
201 infected supernatants used as controls were prepared under same procedure without virus
202 infection.

203 **Gene-silencing.** RNA transcription was performed utilizing T7/SP6 Megascript® Kits (Ambion™)
204 following manufacturer instructions. Briefly, a template DNA containing both promoter sequences
205 were obtained by RT-qPCR for dsAGO2 and dsDENV; by PCR amplification from a pGL3-Basic
206 plasmid (Promega Inc.) containing the Firefly luciferase sequence for dsFLUC; and by PCR
207 amplification from plasmid pDSAG (Addgene #62289) for dsGFP. Primer sequences are available
208 in Supplementary Table 2. Adult 4 days old females were intrathoracically injected with 69 nL of
209 a double-stranded RNA (dsRNA) solution (7.2 µg/µL) diluted in annealing buffer (20mM Tris-HCl
210 pH 7.5, 100mM NaCl) using a nano-injector Nanoject II™ (Drummond Scientific Company).
211 Mosquitoes were allowed to recover for 48 hours prior to feeding or virus injection.

212 **Mosquito strains.** For initial experiments of natural resistance, we also utilized F1 and F2
213 generations of wild *A. aegypti* mosquitoes raised in the laboratory from eggs collected in three
214 neighborhoods of Rio de Janeiro (Humaita, Tubiacanga and Belford Roxo), in southeastern Brazil.
215 For silencing experiments, we utilized mosquitoes from the Red-eye strain³⁰. For the generation
216 of transgenic individuals, wild-type mosquitoes without docking sites were selected from strain 12
217 of BEI Resources (NIAID, NIH: *A. aegypti*, Strain Line 12, MRA-863, contributed by Paul
218 Eggleston). Wild and laboratory mosquito colonies show similar prevalence of infection and viral
219 loads after feeding on a DENV-infected blood meal.

220 **Mosquito rearing and infections.** *A. aegypti* mosquitoes were maintained in an incubator at
221 28°C and 70-80% relative humidity, in a 12:12 hour light:dark photoperiod, and 10% sucrose
222 solution *ad libitum*. For infections by membrane feeding, 5-6 day old adult females were starved
223 for 24h and fed with a mixture of blood and virus supernatant containing 10⁷ PFU/mL of DENV4
224 utilizing a glass artificial feeding system covered with pig intestine membrane. For mosquito
225 infections utilizing mice, we used previously described models for flavivirus infections in IFN
226 deficient animals³¹. AG129 and A129 mice were injected intraperitoneally with 10⁶ PFU of DENV1
227 and ZIKV, respectively. Infected mice were anaesthetized 3 days post infection (peak of viremia)
228 using ketamine/xylazine (80/8 mg per kg) and placed on top of the netting-covered containers
229 with 5-6 day old adult mosquito females. Mosquitoes were allowed to feed on mice for 1h. After
230 blood feeding, fully engorged females were selected and harvested individually for RNA extraction
231 or dissection at different time points. Mosquitoes infected by injection were anesthetized with
232 carbon dioxide and kept on ice during the whole procedure. Virus stocks were diluted with L15
233 medium and injections were performed as previously described for gene-silencing procedure.
234 Each individual mosquito was injected with 160 PFU of DENV unless stated otherwise.
235 Mosquitoes were harvested at different days post injection for RNA extraction. Tissues or
236 mosquitoes were grounded in TRIzol® (Invitrogen™) using glass beads as previously described⁹.

237 Total RNA was extracted from individual mosquitoes or individual tissues according to
238 manufacturer's protocol.

239 **RT-qPCR.** 200 ng of total RNA extracted from individual insects or individual tissues were reverse
240 transcribed using MMLV reverse transcriptase. cDNA was subjected to quantitative polymerase
241 chain reaction (qPCR) utilizing the kit Power SYBR[®] Green Master Mix (Applied Biosystems)
242 following manufacturer instructions. Specific primers are listed on Supplementary Table 2.

243 **Strand-specific RT-PCR.** Total RNA was used in each cDNA reaction, being made 4 reactions
244 at a time: DENV cDNAs of both polarities were reverse transcribed from primers containing a 5'
245 tag sequence³². Mosquito mRNAs were reverse transcribed using oligo (dT)₁₈, and negative
246 control reactions were carried out without addition of primers. First, a mixture of total RNA (200
247 ng), dNTP (10 nmol each) and primers (2 fmol for specific oligos or 100 fmol for oligo (dT)₁₈) was
248 incubated for 5 min at 70°C and for 2 min at 52°C. Samples were immediately incubated on ice
249 and a reaction mix containing Superscript[™] III (200 U) (Invitrogen[™]), First-Strand Buffer (1X)
250 and DTT (100 mmol) was added. Samples were incubated for 55 min at 52°C, followed by an
251 incubation of 15 min at 70°C for enzyme inactivation. Unincorporated primers were digested by a
252 30 min incubation at 37°C with exonuclease I (50 U) (New England Biolabs). 2 µL of each cDNA
253 was used for PCR amplification with Platinum[®] Taq DNA polymerase (Invitrogen[™]) and specific
254 primers (Supplementary Table 2) following standard recommendations from the manufacturer.

255 **Indirect immunofluorescence assays (IFA).** Mosquitoes were anesthetized with carbon
256 monoxide and kept in ice-cold PBS solution (13 mM NaCl, 0.7 mM Na₂HPO₄, 1 mM NaH₂PO₄ at
257 pH 7.2) during dissection process. Midguts were fixed in 4% paraformaldehyde for 30 min at 25°C,
258 washed with PBS twice for 5 min and incubated for 1 h in blocking solution PBST (1X PBS + 1%
259 Bovine Serum Albumin + 0.1 % Triton X-100) with rocking at 25°C. Flavivirus E protein was
260 detected using the 4G2 monoclonal antibody (ATCC: HB-112, used at 1:50 in PBST) for 1h at
261 25°C . Midguts were washed 5 times with PBST (5 min each) and incubated for 1 h with constant
262 rocking at 25°C with goat anti-mouse IgG antibody conjugated to Alexa 488 (Molecular Probes[™],

263 1:500), Hoechst 33342 (Trihydrochloride, Trihydrate - Molecular Probes™, 1:1000) and
264 Phalloidin-Rhodamine (Molecular Probes™, 1:500). Subsequently, midguts were washed twice
265 with PBST with constant rocking at 25°C for 90 min, rinsed with PBS and placed onto slides.
266 Images were obtained with Apotome.2 microscope (Zeiss). Area measurements of infection foci
267 were performed using ImageJ v1.51e (<https://imagej.nih.gov/ij/>).

268 **Small RNA library construction and bioinformatic analyses.** Two strategies for library
269 construction were used as indicated in Supplementary Table 2. (i) Small RNAs were selected by
270 size (18–30 nt) on a denaturing PAGE before being used for construction of libraries as previously
271 described³³. In this case, RNA adaptors containing 4 random nucleotides at 5' and 3' extremities
272 were used to prevent cloning bias as described before^{9,34}. (ii) Total RNA was used as input for
273 library preparation utilizing the TruSeq® Small RNA Library Prep Kit (Illumina®). Both strategies
274 yielded similar results. After sequencing, raw sequenced reads from small RNA libraries were
275 submitted to adaptor trimming using cutadapt³⁵ v1.12, discarding sequences smaller than 18 nt.
276 Remaining sequences were mapped to *A. aegypti* reference genome (AaeL3.3), DENV genome
277 and *A. aegypti* Tefam transposable elements (<https://tefam.biochem.vt.edu/tefam/>) using
278 Bowtie³⁶ v1.1.2 allowing no mismatches and discarding reads mapping on multiple regions. Size
279 profiles of small RNAs matching DENV genome and 5' nt frequency were calculated using in-
280 house Perl v5.16.3, BioPerl library v1.6.924 and R v3.3.1 scripts. Plots were made in R using
281 ggplot2 v2.2.0 package. Transcriptome analysis of public data was performed using raw reads as
282 input for STAR³⁷ v2.5.2b, following normalization by RSEM³⁸ v1.2.31 and edgeR³⁹ v3.16.5.

283 **Phylogenetic analysis.** Protein sequences containing DS_RBD (Double-stranded RNA-binding
284 domain), InterPRO accession IPR014720, were retrieved from Flybase, VectorBase and
285 WormBase, respectively (gene accession identifiers: *D. melanogaster* - CG7138 (*r2d2*), CG6866
286 (*loquacious*); *A. aegypti* - AAEL011753 (*r2d2*), AAEL008687 (*loquacious*), AAEL013721 (*loqs2*);
287 *A. albopictus* - AALF015406 (*r2d2*), AALF018531 (*loquacious*), AALF016290 (*loqs2*); *C.*
288 *quinquefasciatus* - CPIJ011746 (*r2d2*), CPIJ004832 (*loquacious*); *A. gambiae* - AGAP009887

289 (*r2d2*), AGAP009781 (*loquacious*); *C. elegans* – T20G5.11 (*rde-4*). Full open reading frames
290 were aligned using ClustalO⁴⁰ v1.2.4 with standard parameters. Phylogenetic tree was
291 constructed using FigTree v1.4.3 (<http://tree.bio.ed.ac.uk/software/figtree>).

292 **Plasmid constructions.** Plasmids were prepared using GoldenGate cloning⁴¹⁻⁴³. Details for main
293 plasmids are described on Supplementary Table 3 and sequences are provided in Supplementary
294 Information. Briefly, DNA fragments were PCR-amplified using Phusion High-Fidelity DNA
295 polymerase (Thermo Scientific™) with oligos described in Supplementary Table 2. PCR products
296 for GoldenGate cloning were designed to have Bsal sites in their extremities. All PCR products
297 were cloned into a modified pBluescriptII KS(+) (Addgene #62540) lacking Bsal restriction site in
298 an one-step digestion/ligation using FastDigest™ SmaI or FastDigest™ EcoRV (Thermo
299 Scientific™) and T4 DNA-ligase (Invitrogen™) with 10mM ATP. Final plasmid assembly by
300 GoldenGate cloning was conducted as described⁴³. Successful cloning was confirmed by Sanger
301 sequencing (GATC Biotech, Germany).

302 **Mosquito Transgenesis.** Embryo microinjection was performed with small modifications as
303 previously described⁴³⁻⁴⁵. Briefly, freshly laid eggs were parallelly aligned against the internal side
304 of a [shaped nitrocellulose membrane kept wet with an overlaying filter paper soaked in
305 demineralized water. Aligned eggs rested in a humid chamber for 30-60 minutes after alignment,
306 until the eggs turned dark-grey. A plasmid mix containing 100 ng/μL of transposase helper-
307 plasmid and 400 ng/μL of plasmids carrying *piggyBac*-flanked cassettes (described in
308 Supplementary table 3) were diluted in 0.5X PBS and were injected at the embryo posterior-pole
309 under a Nikon Eclipse TE2000-S inverted microscope using a Femtojet injector (Eppendorf) and
310 a TransferMan NK2 micromanipulator. Before being dried, microinjected eggs were allowed to
311 rest for 2 days placed diagonally in a container with 1-cm-deep water. The filter-paper had direct
312 contact with water that maintained the eggs wet by capillarity. Surviving eggs were hatched under
313 vacuum and larvae showing transient expression of fluorescent markers were kept for further
314 crossing to an excess of wild-type mosquitoes. Single transgenic females were crossed to wild-

315 type males to start isofamilies. Infection experiments performed with 3 independent transgenic
316 lines carrying single insertions of the transgene showed similar phenotypes.

317 **Immunoprecipitation of Loqs2.** *A. aegypti* Aag2 cells were grown at 25°C in Schneider medium
318 supplemented with 10% FBS, 1% penicillin-streptomycin and 1% GlutaMAX™ (Gibco). Prior
319 transfection, 3 x 10⁶ cells were seeded in each well of a 6 wells plates and transfected with 800
320 ng of plasmid DNA using Effectene Reagent (QUIAGEN), following manufacturer instructions.
321 Media was replaced 18 h after transfection and cells were allowed to grow for 4 days. Plasmid
322 sequences are described in Supplementary Table 3. Cells were washed and harvested in ice-
323 cold 1X PBS, pelleted by centrifugation at 4°C and Lysis buffer (30 mM HEPES KOH pH 7.5, 50
324 mM NaCl, 2 mM Mg(OAC)₂, 1% NP40 and Roche protease inhibitor cocktail) was added. Flag-
325 Loqs2 and Flag-eGFP proteins were immunoprecipitated using magnetic microparticles coated
326 with a monoclonal anti-Flag antibody (µMACS magnetic microbeads - MACS purification system,
327 Miltenyi Biotech) according to the manufacturer's instructions and as previously described⁴⁶. Flag-
328 eGFP was used as a negative control. Immunoprecipitation experiments were carried out in
329 triplicates.

330 **Mass spectrometry analysis.** Eluted proteins were digested with sequencing-grade trypsin
331 (Promega) and analyzed by nanoLC-MS/MS on a TripleTOF 5600 mass spectrometer (Sciex,
332 USA) coupled to nanoLC-ultra-2D-plus liquid chromatography (Eksigent, Sciex Separations,
333 USA) as described previously⁴⁷. Data were searched against the UniProtKB database (*Aedes*
334 *aegypti*, taxon 7159, release 2018_03, 24.927 sequences) with a decoy strategy. Peptides were
335 identified with Mascot algorithm⁴⁸ (version 2.5, Matrix Science, London, UK) and data were further
336 imported into Proline 1.4 software (<http://proline.profiroteomics.fr>). Proteins were validated on
337 Mascot pretty rank equal to 1, and 1% FDR on both peptide spectrum matches (PSM score) and
338 protein sets (Protein Set score). The total number of MS/MS fragmentation spectra was used to
339 quantify each protein from at least three independent biological replicates. This spectral count
340 was submitted to a negative-binomial test using an edgeR³⁹ GLM regression through R v3.2.5.

341 For each identified protein, an adjusted p -value corrected by Benjamini–Hochberg was calculated,
342 as well as a protein fold-change (FC). The results are presented in a Volcano plot using protein
343 \log_2 fold changes and their corresponding adjusted \log_{10} p -values to highlight upregulated
344 proteins. Data are available via ProteomeXchange with identifier PXD010191.

345 **Statistical analyses.** Evaluation of statistical significance was performed using GraphPad
346 Prism™ software or stated otherwise. Viral loads of RT-qPCR positive-only individual
347 mosquito/tissues were log transformed and subjected to Mann-Whitney U test. Prevalence of
348 infection was evaluated by Fisher’s exact test. The significance of differential gene expression of
349 RNAi components was evaluated using multiple t -tests and Holm-Sidak correction method for
350 multiple comparisons. Pearson correlation coefficient was calculated for each group of samples
351 using log-transformed values of normalized viral load (by RpL32 mRNA expression) and
352 normalized siRNA counts (by total number of reads mapping on *A. aegypti* genome).

353

354 **Data availability**

355 Small RNA libraries from this study were deposited on *Sequence Read Archive* (SRA) at NCBI.
356 Other publicly available RNA-seq datasets were obtained from SRA. Accession numbers and
357 references are described in Supplementary Table 4.

358

359 **Correspondence and requests for materials** should be addressed to J.T.M. (jtm@ufmg.br).

360

361 **Acknowledgments**

362 We thank Claudia N. D. dos Santos for kindly providing 4G2 monoclonal antibodies. This work
363 was supported with funding from Conselho Nacional de Desenvolvimento Científico e
364 Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
365 and Fundação de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG) to J.T.M.; Agence
366 Nationale de la Recherche (ANR-11-ASV3-002), Investissement d'Avenir Programs (ANR-10-
367 LABX-36; ANR-11-EQPX-0022) to J.T.M and J.-L.I.; Inserm, CNRS and the University of
368 Strasbourg to E.M. and J.-L.I.; mass spectrometry instrumentation was funded by University of
369 Strasbourg, IdEx Equipement mi-lourd 2015 to L.K. and P.H.. National and/or international
370 fellowships from CAPES were granted to R.P.O., T.C.I.-T., A.G.A.F., E.R.G.R.A., K.P.R.S.,
371 K.P.O., and C.D.O.; national and/or international fellowships from CNPq were granted to I.J.S.F.,
372 L.A.M. and J.T.M..

373

374 **Author contributions**

375 R.P.O. and J.T.M. designed the project. R.P.O., A.G.A.F., T.C.I.-T., I.J.S.F., K.P.R.S., K.P.O.,
376 P.H., E.G.A., Y.M.T, M.N.R., T.H.J.F.L., S.C.G.A., J.N.A., S.P. performed experiments. R.P.O.,
377 E.R.G.R.A. and L.K. performed bioinformatics analysis. C.D.O., F.D.C., L.A.M and E.M.
378 contributed to mosquito experiments. R.P.O., E.R.G.R.A., J.-L.I. and J.T.M. analyzed the data.

379 R.P.O., J.-L.I. and J.T.M. wrote the paper. All authors discussed the results and commented on
380 the manuscript.

381

382 **Competing interests**

383 The authors declare no competing financial interests.

384

385 **Additional information**

386 Supplementary information is available online. Reprints and permissions information is available
387 online at www.nature.com/reprints.

388

389 **Figure legends**

390

391 **Figure 1 - Production of DENV-derived siRNAs in infected mosquitoes.** (a) Mosquitoes were
392 fed on a blood meal containing 10^7 PFU/mL of DENV and tested individually by RT-qPCR to
393 detect viral RNA levels. After 4 days post feeding (dpf), three different groups were observed:
394 mosquitoes with detectable viral RNA at high or low viral loads (full circles), and individuals with
395 undetected viral load (open circles). Control mosquitoes were fed on a blood meal without virus.
396 The dashed line indicates the lower limit of viral RNA levels detected at 2 dpf. (b) Detection of the
397 DENV antigenome as an indication of productive viral replication in pools of mosquitoes from
398 each group. This experiment is representative of three biological replicates. **c-f** Size distribution
399 and 5' base frequency of DENV-derived small RNA sequences from different mosquito groups:
400 (c) high viral load, (d) low viral load, (e) undetected viral load and (f) controls. Positive and
401 negative values reflect sequences that matched the sense and antisense strands of the viral
402 genome, respectively. Viral load of each RNA pool is indicated in each plot. (g) Mosquitoes were
403 intrathoracically injected with 160 PFU of DENV and tested individually by RT-qPCR to detect the
404 viral RNA. (h) Size distribution and 5' base frequency of DENV-derived small RNA sequences
405 from mosquitoes injected with DENV at different times after infection. dpf, days post feeding; dpi,
406 days post injection. In **a** and **g**, numbers of infected individuals over the total number of
407 mosquitoes are indicated above each column. Each dot represents a mosquito. Bars show
408 median and interquartile range. Only mosquitoes with detectable viral load were considered for
409 statistical analyses.

410

411 **Figure 2 – The antiviral siRNA pathway does not control DENV infection in the mosquito**
412 **midgut but inhibits systemic dissemination and replication.** (a) Detailed strategy to analyze
413 DENV infection in mosquitoes by measuring viral load by RT-qPCR or detection of envelope (E)
414 protein by immunofluorescence (IFA) microscopy. (b) DENV RNA levels and (c) prevalence of

415 infection in the midgut of mosquitoes treated with dsAGO2 or dsFLUC at indicated time points
416 after feeding on an DENV-contaminated blood meal. Numbers of infected individuals over the
417 total are indicated above each tested condition. In **c** numbers of infected midguts over the total
418 number analyzed are indicated above each column. Each dot represents a midgut from a single
419 mosquito. (**d**) Number of foci per midgut of DENV infected mosquitoes treated with dsAGO2 or
420 dsFLUC at 3 and 4 days post feeding. $n = 13$ and $n = 15$ midguts of dsFLUC or dsAGO2 treated
421 mosquitoes, respectively. (**e**) Size of DENV infected foci in the midgut of mosquitoes treated with
422 dsAGO2 or dsFLUC at 3 and 4 dpf. Error bars represent median and interquartile range. $n = 34$
423 and $n = 31$ DENV foci from midguts of dsFLUC or dsAGO2 treated mosquitoes, respectively. Two-
424 tailed Mann-Whitney U test was performed in **b**, **d** and **e**. Two-tailed Fisher's exact test was used
425 in **c**. *ns*, non-significant. (**f**) Prevalence of DENV infection and (**g**) DENV RNA levels in the carcass
426 of mosquitoes treated with dsAGO2 or dsFLUC at indicated time points after feeding on an
427 infectious blood meal. Numbers of infected individuals over the total are indicated above each
428 condition. (**h**) DENV RNA levels in mosquitoes treated with dsAGO2 or dsFLUC and injected
429 intrathoracically with DENV to mimic systemic infection. In **f** and **h**, error bars represent median
430 and interquartile range, statistical significance was determined by two-tailed Mann-Whitney U test.
431 *ns*, non-significant. Numbers of infected carcasses (**f**) or whole mosquitoes (**g**) over the total
432 number tested are indicated above each column where each dot represents an individual sample.
433 Bars show median and interquartile range. In **g**, *p*-values are indicated based on two-tailed
434 Fisher's exact test.

435

436 **Figure 3 – The siRNA pathway triggered by endogenous and exogenous sources of dsRNA**
437 **is functional in the midgut.** (**a**) Expression levels of siRNA pathway components based on
438 individual RNAseq libraries from embryos (em, $n = 3$), adult whole bodies (wb, $n = 6$), brains (br,
439 $n = 3$), salivary glands (sg, $n = 2$), ovaries (ov, $n = 2$) and midguts (mi, $n = 6$). FPKM, fragments per
440 kilobase per million. Bars represent mean and standard deviation. Two-tailed one-way ANOVA

441 followed by Dunnet's test was applied. *ns*, not significant. **(b)** Transposable element (TE)-derived
442 siRNA levels in the midgut of mosquitoes treated with dsAGO2 or dsFLUC. RPM, reads per
443 million. n=150. Two-tailed paired *t*-test with Holm-Sidak correction method for multiple
444 comparisons was applied. **(c)** Size distribution and 5' base frequency of DENV-derived small RNA
445 sequences in the midgut of mosquitoes injected with dsRNA targeting the NS3 region of DENV
446 genome (dsDENV). The plot on bottom shows the density of siRNAs on the DENV genome.
447 dsRNA target region is indicated by a black bar. **(d)** DENV viral load in the midgut of mosquitoes
448 treated with dsDENV or dsFLUC at 4 dpf. Numbers of infected midguts over the total number
449 tested are indicated above each column. Each dot represents a midgut from a single mosquito.
450 Bars show median and interquartile range. Two-tailed Mann-Whitney U test was applied. **(e)**
451 Prevalence of DENV infection in the midguts from **d**. Two tailed Fisher's exact test was applied. **(f)**
452 Size distribution and 5' base frequency of DENV-derived small RNAs in the midgut or carcasses
453 of mosquitoes with disseminated viral infection. DENV load in each RNA sample is indicated in
454 the plot.

455

456 **Figure 4 – The *Aedes*-specific dsRBP *Loqs2* regulates the antiviral arm of the mosquito**
457 **siRNA pathway.** **(a)** Phylogeny of dsRNA binding proteins (dsRBPs) found in the genomes of *D.*
458 *melanogaster* (Dm), *Anopheles gambiae* (Ag), *Culex quinquefasciatus* (Cq), *A. aegypti* (Ae),
459 *Aedes albopictus* (Aa) and *C. elegans* (Ce). Domain organization for each dsRBP is indicated.
460 **(b)** Viral RNA levels upon DENV injection in dsLoqs2 treated mosquitoes compared to controls
461 (dsGFP). Numbers of infected whole mosquitoes over the total number tested are indicated above
462 each column. Each dot represents an individual mosquito. Bars show median and interquartile
463 range. Two-tailed Mann-Whitney U test was applied. **(c)** Construct for inducible expression of
464 *loqs2* in *A. aegypti* under the control of the *carboxypeptidase* (*CP*) promoter. **(d)** Fluorescent
465 marker expression in transgenic larvae. Results are representative of images observed with at
466 least three independent transgenic lines. **(e)** *loqs2* mRNA levels in the carcass and midgut of

467 control and transgenic mosquitoes upon blood feeding. Bars represent mean and standard
468 deviation. Number of independent biological samples is indicated in the figure. ND, not detected.
469 (f) Viral RNA levels and (g) prevalence of infection in the midgut of control and transgenic
470 mosquitoes at indicated time points after feeding on DENV infected mice. (h) Viral RNA levels
471 and (i) prevalence of infection in the carcass of control and transgenic mosquitoes at indicated
472 time points after feeding on DENV infected mice. In f and h, numbers of infected midguts (f) or
473 carcasses (h) over the total number tested are indicated above each column. Each dot represents
474 an individual midgut (f) or carcass (h). Bars show median and interquartile range. Two-tailed
475 Mann-Whitney U test was applied. In g and i, two-tailed Fisher's exact test was applied. *ns*, non-
476 significant. (j) Proteins enriched in immunoprecipitates of Loqs2 (right side of the graph)
477 compared to the control (GFP, left side of the graph). Spectral counts were submitted to a
478 negative-binomial test using GLM regression. *p*-values were corrected using the Benjamini-
479 Hochberg method. n=3 independent samples.

480

481 **References**

- 482 1 Guzman, M. G., Gubler, D. J., Izquierdo, A., Martinez, E. & Halstead, S. B. Dengue
483 infection. *Nature reviews. Disease primers* **2**, 16055 (2016).
- 484 2 Sanchez-Vargas, I. *et al.* Dengue virus type 2 infections of *Aedes aegypti* are modulated
485 by the mosquito's RNA interference pathway. *PLoS Pathog* **5**, e1000299 (2009).
- 486 3 Khoo, C. C. H., Piper, J., Sanchez-Vargas, I., Olson, K. E. & Franz, A. W. E. The RNA
487 interference pathway affects midgut infection- and escape barriers for Sindbis virus in
488 *Aedes aegypti*. *BMC Microbiol* **10**, 130 (2010).
- 489 4 Franz, A. W. *et al.* Engineering RNA interference-based resistance to dengue virus type
490 2 in genetically modified *Aedes aegypti*. *Proc Natl Acad Sci U S A* **103**, 4198-4203 (2006).
- 491 5 Campbell, C. L. *et al.* *Aedes aegypti* uses RNA interference in defense against Sindbis
492 virus infection. *BMC Microbiol* **8**, 47 (2008).
- 493 6 Hess, A. M. *et al.* Small RNA profiling of Dengue virus-mosquito interactions implicates
494 the PIWI RNA pathway in anti-viral defense. *BMC Microbiol* **11**, 45 (2011).
- 495 7 Miesen, P., Ivens, A., Buck, A. H. & van Rij, R. P. Small RNA Profiling in Dengue Virus 2-
496 Infected *Aedes* Mosquito Cells Reveals Viral piRNAs and Novel Host miRNAs. *PLoS Negl*
497 *Trop Dis* **10**, e0004452-0004422 (2016).
- 498 8 Villalon, J. M., Ghosh, A. & Jacobs-Lorena, M. The peritrophic matrix limits the rate of
499 digestion in adult *Anopheles stephensi* and *Aedes aegypti* mosquitoes. *Journal of insect*
500 *physiology* **49**, 891-895 (2003).
- 501 9 Aguiar, E. R. G. R., Olmo, R. P. & Marques, J. T. Virus-derived small RNAs: molecular
502 footprints of host-pathogen interactions. *Wiley Interdiscip Rev RNA* (2016).
- 503 10 Richardson, J., Molina-Cruz, A., Salazar, M. I. & Black, W. t. Quantitative analysis of
504 dengue-2 virus RNA during the extrinsic incubation period in individual *Aedes aegypti*. *Am*
505 *J Trop Med Hyg* **74**, 132-141 (2006).

506 11 Salazar, M. I., Richardson, J. H., Sánchez-Vargas, I., Olson, K. E. & Beaty, B. J. Dengue
507 virus type 2: replication and tropisms in orally infected *Aedes aegypti* mosquitoes. *BMC*
508 *microbiology* **7**, 9 (2007).

509 12 Carthew, R. W. & Sontheimer, E. J. Origins and Mechanisms of miRNAs and siRNAs. *Cell*
510 **136**, 642-655 (2009).

511 13 Ghildiyal, M. *et al.* Endogenous siRNAs Derived from Transposons and mRNAs in
512 *Drosophila* Somatic Cells. *Science* **320**, 1077-1081 (2008).

513 14 Marques, J. T. *et al.* Functional specialization of the small interfering RNA pathway in
514 response to virus infection. *PLoS Pathog* **9**, e1003579 (2013).

515 15 Ashe, A. *et al.* A deletion polymorphism in the *Caenorhabditis elegans* RIG-I homolog
516 disables viral RNA dicing and antiviral immunity. *eLIFE* **2**, e00994 (2013).

517 16 Hartig, J. V., Esslinger, S., Böttcher, R., Saito, K. & Förstemann, K. Endo-siRNAs depend
518 on a new isoform of loquacious and target artificially introduced, high-copy sequences.
519 *EMBO J* **28**, 2932-2944 (2009).

520 17 Hartig, J. V. & Förstemann, K. Loqs-PD and R2D2 define independent pathways for RISC
521 generation in *Drosophila*. *Nucleic Acids Res* **39**, 3836-3851 (2011).

522 18 Haac, M. E., Anderson, M. A., Eggleston, H., Myles, K. M. & Adelman, Z. N. The hub
523 protein loquacious connects the microRNA and short interfering RNA pathways in
524 mosquitoes. *Nucleic Acids Res* **43**, 3688-3700 (2015).

525 19 Marques, J. T. *et al.* Loqs and R2D2 act sequentially in the siRNA pathway in *Drosophila*.
526 *Nat Struct Mol Biol* **17**, 24-30 (2010).

527 20 Tabara, H., Yigit, E., Siomi, H. & Mello, C. C. The dsRNA binding protein RDE-4 interacts
528 with RDE-1, DCR-1, and a DExH-box helicase to direct RNAi in *C. elegans*. *Cell* **109**, 861-
529 871 (2002).

530 21 Parrish, S. & Fire, A. Distinct roles for RDE-1 and RDE-4 during RNA interference in
531 *Caenorhabditis elegans*. *RNA* **7**, 1397-1402 (2001).

- 532 22 Edwards, M. J. *et al.* Characterization of a carboxypeptidase A gene from the mosquito,
533 *Aedes aegypti*. *Insect Mol Biol* **9**, 33-38 (2000).
- 534 23 Carissimo, G. *et al.* Antiviral immunity of *Anopheles gambiae* is highly compartmentalized,
535 with distinct roles for RNA interference and gut microbiota. *Proc Natl Acad Sci U S A* **112**,
536 E176-185 (2015).
- 537 24 Sarkies, P. *et al.* Ancient and novel small RNA pathways compensate for the loss of
538 piRNAs in multiple independent nematode lineages. *PLoS Biol* **13**, e1002061 (2015).
- 539 25 Maillard, P. V. *et al.* Antiviral RNA interference in mammalian cells. *Science* **342**, 235-238
540 (2013).
- 541 26 Li, Y., Lu, J., Han, Y., Fan, X. & Ding, S. W. RNA interference functions as an antiviral
542 immunity mechanism in mammals. *Science* **342**, 231-234 (2013).
- 543 27 Pereira, T. N., Rocha, M. N., Sucupira, P. H. F., Carvalho, F. D. & Moreira, L. A. Wolbachia
544 significantly impacts the vector competence of *Aedes aegypti* for Mayaro virus. *Sci Rep* **8**,
545 6889 (2018).
- 546 28 Donald, C. L. *et al.* Full Genome Sequence and sfRNA Interferon Antagonist Activity of
547 Zika Virus from Recife, Brazil. *PLoS Negl Trop Dis* **10**, e0005048 (2016).
- 548 29 Sedda, L. *et al.* The spatial and temporal scales of local dengue virus transmission in
549 natural settings: a retrospective analysis. *Parasites & vectors* **11**, 79 (2018).
- 550 30 Barletta, A. B. *et al.* Microbiota activates IMD pathway and limits Sindbis infection in *Aedes*
551 *aegypti*. *Parasites & vectors* **10**, 103 (2017).
- 552 31 Tan, G. K. *et al.* A non mouse-adapted dengue virus strain as a new model of severe
553 dengue infection in AG129 mice. *PLoS Negl Trop Dis* **4**, e672 (2010).
- 554 32 Lanford, R. E., Sureau, C., Jacob, J. R., White, R. & Fuerst, T. R. Demonstration of in vitro
555 infection of chimpanzee hepatocytes with hepatitis C virus using strand-specific RT/PCR.
556 *Virology* **202**, 606-614 (1994).
- 557 33 Pfeffer, S. *et al.* Identification of virus-encoded microRNAs. *Science* **304**, 734-736 (2004).

558 34 Jayaprakash, A. D., Jabado, O., Brown, B. D. & Sachidanandam, R. Identification and
559 remediation of biases in the activity of RNA ligases in small-RNA deep sequencing.
560 *Nucleic Acids Res* **39**, e141 (2011).

561 35 Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads.
562 *EMBnet.journal* **17** (2011).

563 36 Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient
564 alignment of short DNA sequences to the human genome. *Genome Biol* **10**, R25 (2009).

565 37 Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15-21
566 (2013).

567 38 Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with
568 or without a reference genome. *BMC Bioinformatics* **12**, 323 (2011).

569 39 Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for
570 differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139-
571 140 (2010).

572 40 Sievers, F. *et al.* Fast, scalable generation of high-quality protein multiple sequence
573 alignments using Clustal Omega. *Mol Syst Biol* **7**, 539 (2011).

574 41 Engler, C. & Marillonnet, S. Combinatorial DNA assembly using Golden Gate cloning.
575 *Methods Mol Biol* **1073**, 141-156 (2013).

576 42 Geissler, R. *et al.* Transcriptional activators of human genes with programmable DNA-
577 specificity. *PLoS One* **6**, e19509 (2011).

578 43 Volohonsky, G. *et al.* Tools for Anopheles gambiae Transgenesis. *G3 (Bethesda)* **5**, 1151-
579 1163 (2015).

580 44 Jasinskiene, N., Juhn, J. & James, A. A. Microinjection of *A. aegypti* embryos to obtain
581 transgenic mosquitoes. *J Vis Exp*, 219 (2007).

582 45 Morris, A. C., Eggleston, P. & Crampton, J. M. Genetic transformation of the mosquito
583 *Aedes aegypti* by micro-injection of DNA. *Med Vet Entomol* **3**, 1-7 (1989).

584 46 Stoetzel, C. *et al.* A mutation in VPS15 (PIK3R4) causes a ciliopathy and affects IFT20
585 release from the cis-Golgi. *Nat Commun* **7**, 13586 (2016).

586 47 Chicher, J. *et al.* Purification of mRNA-programmed translation initiation complexes
587 suitable for mass spectrometry analysis. *Proteomics* **15**, 2417-2425 (2015).

588 48 Perkins, D. N., Pappin, D. J. C., Creasy, D. M. & Cottrell, J. S. Probability-based protein
589 identification by searching sequence databases using mass spectrometry data.
590 *Electrophoresis* **20**, 3551-3567 (1999).

591

Figure 1




Figure 2




Figure 3




Figure 4

a dsRNA binding motif (IPR014720)

